home>neurologie>forschung>schlaganfall Seite teilen:

Arbeitsgruppe Schlaganfall

Ausgewählte Publikationen

The Dimension of Preventable Stroke in a Large Representative Patient Cohort
Christian Boehme, Thomas Toell, Lukas Mayer, Lena Domig, Raimund Pechlaner, Karin Willeit, Lena Tschiderer, Lisa Seekircher, Peter Willeit, Andrea Griesmacher, Michael Knoflach, Johann Willeit, Stefan Kiechl
Neurology, 93 (23), e2121-e2132 2019 Dec 3

There is a considerable gap between risk factor control recommended by guidelines and real-world stroke prevention

Risk Thresholds for Alcohol Consumption: Combined Analysis of Individual-Participant Data for 599 912 Current Drinkers in 83 Prospective Studies.
Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group.
Lancet , 391 (10129), 1513-1523, 2018 Apr 14

These data support limits for alcohol consumption that are lower than those recommended in most current guidelines.

Higher spermidine intake is linked to lower mortality: a prospective population-based study.
Kiechl S, Pechlaner R, Willeit P, Notdurfter M, Paulweber B, Willeit K, Werner P, Ruckenstuhl C, Iglseder B, Weger S, Mairhofer B, Gartner M, Kedenko L, Chmelikova M, Stekovic S, Stuppner H, Oberhollenzer F, Kroemer G, Mayr M, Eisenberg T, Tilg H, Madeo F, Willeit J.
Am J Clin Nutr. 2018;108:371-380

This is the first epidemiological study to demonstrate an association between diet rich in spermidine and reduced risk of death.

Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study
Willeit J, Geley T, Schöch J, Rinner H, Tür A, Kreuzer H, Thiemann N, Knoflach M, Toell T, Pechlaner R, Willeit K, Klingler N, Praxmarer S, Baubin M, Beck G, Berek K, Dengg C, Engelhardt K, Erlacher T, Fluckinger T, Grander W, Grossmann J, Kathrein H, Kaiser N, Matosevic B, Matzak H, Mayr M, Perfler R, Poewe W, Rauter A, Schoenherr G, Schoenherr HR, Schinnerl A, Spiss H, Thurner T, Vergeiner G, Werner P, Wöll E, Willeit P, Kiechl S
The Lancet Neurology 2015;14:48-56

This paper was awarded with the INTEGRI-AWARD
During the period of implementation of our comprehensive stroke management programme, thrombolysis administration increased and clinical outcome significantly improved, although mortality did not change. We hope that these results will guide health authorities and stroke physicians elsewhere when implementing similar programmes for patients with stroke.

Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck Study
Stegemann C*, Pechlaner R*, Willeit P, Langley S, Mangino M, Mayr U, Menni C, Moayyeri A, Santer P, Rungger G, Spector TD, Willeit J, Kiechl S, Mayr M
Circulation 2014;129:1821-1831
*These authors contributed equally

This study applied mass spectrometry-based lipidomics profiling to population-based cohorts and identified molecular lipid signatures for cardiovascular disease. Molecular lipid species constitute promising new biomarkers that outperform the conventional biochemical measurements of lipid classes currently used in the clinics.

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.
Natriuretic Peptides Studies Collaboration, Willeit P et al.
Lancet Diabetes Endocrinol 2016;10:840-9

In an evaluation of 40 prospective studies with a total of 95,617 study participants, Peter Willeit showed that the increased levels of the natriuretic peptide NT-proBNP was associated with an increased risk of cardiovascular diseases. The strength of this association was comparable to that of HDL cholesterol (Figure). This work also describes the fact that the measurement of NT-proBNP in addition to the detection of standard risk factors significantly improves the prediction and thus can lead to an optimization of the primary prevention of these diseases.

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus
Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, Moschen AR, Muscogiuri G, Sorice GP, Kireva T, Summerer M, Wirtz S, Luther J, Mielenz D, Billmeier U, Egger G, Mayr A, Oberhollenzer F, Kronenberg F, Orthofer M, Penninger JM, Meigs JB, Bonora E, Tilg H, Willeit J, Schett G.
Nature Medicine 2013;19:358-363

This study provides strong evidence for a role of RANKL signaling in the pathogenesis of hepatic insulin resistance and T2DM, provides a link between inflammation and disrupted glucose homeostasis and holds promise for the future development of new therapeutic and preventive approaches.

C-reactive protein, fibrinogen, and cardiovascular disease prediction
The Emerging Risk Factors Collaboration
N Engl J Med 2012;367:1310-1320

Diabetes mellitus, fasting glucose, and risk of cause-specific death
The Emerging Risk Factors Collaboration
N Engl J Med 2011;364:829-841

J. Willeit and S. Kiechl are members of the writing committee of the ERFC which has published more than ten individual data meta-analysis on cardiovascular risk factors and risk prediction. The two papers presented here elaborate the association between diabetes and cause-specific mortality and the usefulness of high-sensitivity CRP in cardiovascular risk prediction.

NEJM

Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.
Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, Oberhollenzer F, Egger G, Witztum JL, Alexander VJ, Willeit J, Kiechl S, Mayr M.
J Am Coll Cardiol 2017;7:789-800

This study reports a strong association of VLDL associated Apolipoproteins with incident cardiovascular disease and may be the basis for a new therapy targeting these Apolipoproteins. Valentin Fuster considered this manuscript as one of the best in his period as the Editor-in-Chief of JACC.

Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques.
Langley SR, Willeit K, Didangelos A, Matic LP, Skroblin P, Barallobre-Barreiro J, Lengquist M, Rungger G, Kapustin A, Kedenko L, Molenaar C, Lu R, Barwari T, Suna G, Yin X, Iglseder B, Paulweber B, Willeit P, Shalhoub J, Pasterkamp G, Davies AH, Monaco C, Hedin U, Shanahan CM, Willeit J, Kiechl S, Mayr M.
J Clin Invest 2017;4:1546-1560

This study is the first to identify a proteom signature of instable plaques.

Do Women With Atrial Fibrillation Experience More Severe Strokes? Results From the Austrian Stroke Unit Registry.
Lang C, Seyfang L, Ferrari J, Gattringer T, Greisenegger S, Willeit K, Toell T, Krebs S, Brainin M Kiechl S, Willeit J, Lang W, Knoflach M; Austrian Stroke Registry Collaborators.
Stroke 2017;48:778-780

It is a well-established fact that women with atrial fibrillation are at increased risk of stroke, yet it is unknown, if there is a sex difference also in stroke severity. We address this question analyzing more than 70.000 patients documented in the Austrian Stroke Unit Registry.

Alle Publikationen

Klinische Studien

Aktuell:

ACST II, PACIFIC-STROKE, BIA-2093-213, CREGS-2, TENSION, SWIFT Direct, Stroke Card Follow-up, ProSect, ERIL, EVA4YOU

Bruneck-Studie

Publikationen

Rezente Bücher und Buchbeiträge:

Basilar Artery - a clinical review (Chapter 21)
Autoren: Lukas Mayer, Michael Knoflach, Johann Willeit, Elke R. Gizewski, Stefan Kiechl
Verlag: Nova
Link

Ultrasound and Carotid Bifurcation Atherosclerosis
Autoren: Andrew Nicolaides, Kirk W. Beach, Efthyvoulos Kyriacou, Constantinos S. Pattichis
Beiträge: Stefan Kiechl, Philipp Werner, Michael Knoflach, Johann Willeit
Verlag: Springer
Link

Nach einem Schlaganfall
Autoren: Stefan Kiechl, Wolfgang Lalouschek, Wilfried Lang
Verlag: Holzhausen
Link

High-Resolution Sonography of the Peripheral Nervous System
Autoren: Hannes Gruber, Peter Kovacs, Stefan Kiechl, Gerd Bodner, Hildegunde Piza-Katzer
Verlag: Springer
Link

Aktuelles:

Startschuss für Comet Zentrum VASCage-C, April 2019

Die 22. Jahrestagung der Österreichischen Schlaganfall Gesellschaft ist heuer in Innsbruck mit großem Erfolg ausgerichtet worden.

Dr. Raimund Pechlaner erhält den Sanofi-Preis 2017 für seine Arbeit zu den Apolipoproteine.

Dr. Karin Willeit erhält den Sanofi-Preis 2018 für ihre Arbeit "Association between vascular cell adhesion molecule 1 and atrial fibrillation".